Search Results for "Chemotherapy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Chemotherapy. Results 11 to 20 of 220 total matches.

Netupitant/Palonosetron (Akynzeo) for Chemotherapy-Induced Nausea and Vomiting

   
The Medical Letter on Drugs and Therapeutics • Apr 27, 2015  (Issue 1467)
Netupitant/Palonosetron (Akynzeo) for Chemotherapy-Induced Nausea and Vomiting ...
The FDA has approved Akynzeo (Helsinn/Eisai), an oral fixed-dose combination of the substance P/neurokinin 1 (NK1) receptor antagonist netupitant and the serotonin-3 (5-HT3) receptor antagonist palonosetron, for prevention of acute and delayed nausea and vomiting associated with cancer chemotherapy in adults. Akynzeo is the first product to combine drugs from these two classes. Palonosetron (Aloxi) is also available as a single agent for prevention of chemotherapy-induced and postoperative nausea and vomiting. Netupitant is the second substance P/NK1 receptor antagonist to be...
Med Lett Drugs Ther. 2015 Apr 27;57(1467):61-3 |  Show IntroductionHide Introduction

Eflapegrastim (Rolvedon) for Prevention of Chemotherapy-Induced Febrile Neutropenia

   
The Medical Letter on Drugs and Therapeutics • May 29, 2023  (Issue 1677)
Eflapegrastim (Rolvedon) for Prevention of Chemotherapy-Induced Febrile Neutropenia ...
Eflapegrastim-xnst ((Rolvedon) [Spectrum]; previously called Rolontis), a granulocyte colony-stimulating factor (G-CSF) conjugated to an Fc fragment of human IgG4, has been approved by the FDA to decrease the incidence of infection, as manifested by febrile neutropenia, in adults with nonmyeloid malignancies receiving myelosuppressive chemotherapy that can cause clinically significant febrile neutropenia.
Med Lett Drugs Ther. 2023 May 29;65(1677):83-4   doi:10.58347/tml.2023.1677b |  Show IntroductionHide Introduction

Dolasetron for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy

   
The Medical Letter on Drugs and Therapeutics • May 08, 1998  (Issue 1026)
Dolasetron for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy ...
Dolasetron (Anzemet - Hoechst Marion Roussel), a selective serotonin (5-HT3) receptor antagonist similar to ondansetron (Zofran) and granisetron (Kytril - Medical Letter, 36:61, 1994) is now available for both oral and intravenous use in prevention of nausea and vomiting due to cancer chemotherapy. A 5-HT3 antagonist plus dexamethasone (Decadron, and others) is the most effective regimen for prevention of acute vomiting caused by cancer chemotherapy. Dolasetron has also been approved by the FDA for prevention and treatment of postoperative nausea and...
Med Lett Drugs Ther. 1998 May 8;40(1026):53-4 |  Show IntroductionHide Introduction

Rolapitant (Varubi) for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting

   
The Medical Letter on Drugs and Therapeutics • Feb 01, 2016  (Issue 1487)
Rolapitant (Varubi) for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting ...
The FDA has approved rolapitant (Varubi – Tesaro), an oral substance P/neurokinin 1 (NK1) receptor antagonist, for use with other antiemetics to prevent delayed nausea and vomiting associated with cancer chemotherapy in adults. It is the third substance P/NK1 receptor antagonist to be approved in the US; aprepitant (Emend) and netupitant (only available in combination with the 5-HT3 receptor antagonist palonosetron as Akynzeo) were approved earlier for prevention of both acute and delayed chemotherapy-induced nausea and vomiting.
Med Lett Drugs Ther. 2016 Feb 1;58(1487):17-8 |  Show IntroductionHide Introduction

Aprepitant (Emend) for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy

   
The Medical Letter on Drugs and Therapeutics • Aug 04, 2003  (Issue 1162)
Aprepitant (Emend) for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy ...
Aprepitant (Emend - Merck), the first substance P/neurokinin 1 (NK1) receptor antagonist to be approved by the FDA, is now available for oral use with corticosteroids and selective serotonin (5-HT3) receptor antagonists to prevent nausea and vomiting caused by highly emetogenic anticancer drugs such as cisplatin.
Med Lett Drugs Ther. 2003 Aug 4;45(1162):62-3 |  Show IntroductionHide Introduction

Palonosetron (Aloxi) for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy

   
The Medical Letter on Drugs and Therapeutics • Mar 29, 2004  (Issue 1179)
Palonosetron (Aloxi) for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy ...
Palonosetron (Aloxi - Helsinn Healthcare SA, Switzerland, distributed in the US by MGI Pharma) is the fourth serotonin (5-HT3) receptor antagonist to become available in the US and the first to be approved by the FDA for prevention of both acute and delayed nausea and vomiting due to moderately emetogenic cancer chemotherapy. It is also approved for prevention of acute nausea and vomiting due to highly emetogenic drugs such as cisplatin (Platinol, and others). Aprepitant (Emend), a substance P/neurokinin-1 receptor antagonist, was approved last year for use with a 5-HT3 antagonist and...
Med Lett Drugs Ther. 2004 Mar 29;46(1179):27-8 |  Show IntroductionHide Introduction

IV Aprepitant (Cinvanti) for Chemotherapy-Induced Nausea and Vomiting (online only)

   
The Medical Letter on Drugs and Therapeutics • Dec 03, 2018  (Issue 1561)
IV Aprepitant (Cinvanti) for Chemotherapy-Induced Nausea and Vomiting (online only) ...
The FDA has approved Cinvanti (Heron), an IV emulsion formulation of the substance P/neurokinin-1 (NK1) receptor antagonist aprepitant, for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Aprepitant is also available in oral capsule and suspension formulations (Emend, and generics), and fosaprepitant, a prodrug of aprepitant, is available in an IV formulation (Emend for injection).
Med Lett Drugs Ther. 2018 Dec 3;60(1561):e200-1 |  Show IntroductionHide Introduction

Tremelimumab (Imjudo) for Metastatic NSCLC (online only)

   
The Medical Letter on Drugs and Therapeutics • Feb 06, 2023  (Issue 1669)
-based chemotherapy for treatment of metastatic non-small cell lung cancer (NSCLC) in adults ...
The FDA has approved tremelimumab-actl (Imjudo – AstraZeneca), a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody, for use in combination with the programmed death-ligand 1 (PD-L1) blocking antibody durvalumab (Imfinzi) and platinum-based chemotherapy for treatment of metastatic non-small cell lung cancer (NSCLC) in adults with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
Med Lett Drugs Ther. 2023 Feb 6;65(1669):e31-2   doi:10.58347/tml.2023.1669h |  Show IntroductionHide Introduction

Ryzneuta for Prevention of Febrile Neutropenia

   
The Medical Letter on Drugs and Therapeutics • Aug 19, 2024  (Issue 1709)
myelosuppressive chemotherapy that can cause clinically significant febrile neutropenia. It is the first ...
Efbemalenograstim alfa-vuxw (Ryzneuta – Evive), a nonpegylated granulocyte colony-stimulating factor (G-CSF) conjugated to an Fc fragment of human IgG2, has been approved by the FDA to decrease the incidence of infection, as manifested by febrile neutropenia, in adults with nonmyeloid malignancies receiving myelosuppressive chemotherapy that can cause clinically significant febrile neutropenia. It is the first nonpegylated, long-acting G-CSF to become available in the US. Two pegylated, long-acting G-CSFs, pegfilgrastim (Neulasta, and biosimilars) and eflapegrastim (Rolvedon), are...
Med Lett Drugs Ther. 2024 Aug 19;66(1709):134-5   doi:10.58347/tml.2024.1709d |  Show IntroductionHide Introduction

Tislelizumab (Tevimbra) for Esophageal Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • May 13, 2024  (Issue 1702)
or metastatic esophageal squamous cell cancer in adults who received prior systemic chemotherapy that did ...
The FDA has approved tislelizumab (Tevimbra – BeiGene), a programmed death receptor-1 (PD-1) blocking antibody, for treatment of unresectable or metastatic esophageal squamous cell cancer in adults who received prior systemic chemotherapy that did not include a programmed death ligand-1 (PD-L1) inhibitor.
Med Lett Drugs Ther. 2024 May 13;66(1702):e85-6   doi:10.58347/tml.2024.1702h |  Show IntroductionHide Introduction